Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck    LUN   DK0010287234

H. LUNDBECK (LUN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
384(c) 388.9(c) 384(c) 380.4(c) 381(c) Last
470 485 326 191 259 674 298 147 206 724 Volume
-3.13% +1.28% -1.26% -0.94% +0.16% Change
More quotes
Financials ( DKK)
Sales 2017 17 344 M
EBIT 2017 4 470 M
Net income 2017 2 638 M
Finance 2017 3 258 M
Yield 2017 1,87%
Sales 2018 18 293 M
EBIT 2018 5 209 M
Net income 2018 3 259 M
Finance 2018 5 288 M
Yield 2018 2,78%
P/E ratio 2017 28,82
P/E ratio 2018 23,52
EV / Sales2017 4,18x
EV / Sales2018 3,85x
Capitalization 75 793 M
More Financials
Company
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.Its product portfolio... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Surperformance© ratings of H. Lundbeck
Trading Rating : Investor Rating :
More Ratings
Latest news on H. LUNDBECK
10/19 H LUNDBECK : Findings from H. Lundbeck A/S Yields New Data on Alzheimer Disease ..
09/12DJTEVA PHARMACEUTICAL INDUSTRIES : Fills CEO Spot After Long Search -- WSJ
09/12 Teva to sell contraceptive brand Paragard in $1.1 billion deal
09/11 Insurers lead European shares higher as Irma, Korea worries ease
09/11DJTeva Finally Appoints New Chief Executive After Months of Speculation -- 3rd ..
09/11DJTEVA PHARMACEUTICAL INDUSTRIES : Names Kare Schultz as New Chief Executive -- 2n..
09/11DJTEVA PHARMACEUTICAL INDUSTRIES : Names Kare Schultz as New Chief Executive -- Up..
09/11 H LUNDBECK : Changes in Executive Management in Lundbeck
09/11DJTEVA PHARMACEUTICAL INDUSTRIES : Finally Appoints New Chief Executive After Mont..
08/31 H LUNDBECK : New Neurons Study Results Reported from H. Lundbeck A/S [A small mo..
More news
Sector news : Pharmaceuticals - NEC
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/14Zacks Investment Research Lowers H. Lundbeck A/S- $HLUYY to Hold  
10/11H. Lundbeck A/S- downgraded by Zacks Investment Research to hold.  
09/24H. Lundbeck A/S- $HLUYY Given Average Rating of “Hold” by Analysts  
09/17A Look At Kare Schultz, The New CEO In Charge Of Teva  
09/14Cerveau Technologies Inc. Signs Collaboration Agreement with H. Lundbeck A/S .. 
More tweets
Qtime:20
News from SeekingAlpha
09/18 TEVA PHARMACEUTICAL : An Opportunity Or A Falling Knife? (Part 2)
09/14 AXOVANT SCIENCES : The Progressively Contentious Alzheimer's Claim
09/11 An Unexpected Management Transition Rocks Lundbeck
09/11 WALL STREET BREAKFAST : Hurricane Irma Pushes Through Florida
09/11 Teva finally gets a new CEO
Chart H. LUNDBECK
Duration : Period :
H. Lundbeck Technical Analysis Chart | LUN | DK0010287234 | 4-Traders
Technical analysis trends H. LUNDBECK
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 15
Average target price 331  DKK
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Lars Søren Rasmussen Chairman
Anders Götzsche CFO & Executive VP-Information Technology
Lars Bang EVP-Supply Operations & Engineering
Anders Gersel Pedersen Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK35.36%12 005
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223